Pharmarise Holdings Corporation provided consolidated earnings guidance for the six months of fiscal year 2023. For the six months, the company expects net sales to be JPY 25,860 million, operating profit to be JPY 768 million, earnings attributable to owners of parent to be JPY 219 million or JPY 23.40 per share.

For the full year, the company expects net sales to be JPY 51,909 million, operating profit to be JPY 1,606 million, earnings attributable to owners of parent to be JPY 543 million or JPY 58.07 per share.